{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T02:04:31Z","timestamp":1772762671986,"version":"3.50.1"},"reference-count":69,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Metabolism & Toxicology"],"published-print":{"date-parts":[[2016,1,2]]},"DOI":"10.1517\/17425255.2016.1110573","type":"journal-article","created":{"date-parts":[[2015,11,17]],"date-time":"2015-11-17T02:23:03Z","timestamp":1447726983000},"page":"115-127","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":11,"title":["Iron-based phosphate binders \u2013 a new element in management of hyperphosphatemia"],"prefix":"10.1517","volume":"12","author":[{"given":"Amy Barton","family":"Pai","sequence":"first","affiliation":[{"name":",","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soo Min","family":"Jang","sequence":"additional","affiliation":[{"name":",","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Wegrzyn","sequence":"additional","affiliation":[{"name":",","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2015,11,16]]},"reference":[{"key":"e_1_3_2_2_1","unstructured":"Papers of special note have been highlighted as either of interest (*) or of considerable interest (**) to readers."},{"key":"e_1_3_2_3_1","first-page":"1489","article-title":"Mineral metabolism, mortality and morbidity in maintenance hemodialysis","volume":"19","author":"Block GA","year":"2004","unstructured":"Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;19:1489\u20131496.","journal-title":"J Am Soc Nephrol"},{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2014.04.014"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(83)90014-4"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.jrn.2007.08.005"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1542-4758.2012.00711.x"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2002.00434.x"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014020212"},{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425250802614886"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2014.58"},{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199102213240804"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(79)90883-3"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh125"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2011.490"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.05880809"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2008.02.298"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00600.x"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1159\/000111061"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2006101089"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2012030223"},{"key":"e_1_3_5_12_1","doi-asserted-by":"crossref","DOI":"10.1097\/PAS.0000000000000385","article-title":"Peculiar histiocytic lesions with massive lanthanum deposition in dialysis patients treated with lanthanum carbonate","author":"Haratake J","year":"2015","unstructured":"Haratake J, Yasunaga C, Ootani A, et al. Peculiar histiocytic lesions with massive lanthanum deposition in dialysis patients treated with lanthanum carbonate. Am J Surg Pathol. 2015 Jun;39(6):767\u2013771.","journal-title":"Am J Surg Pathol"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1159\/000149239"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0224-6"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.3109\/03639045.2013.838583"},{"key":"e_1_3_5_16_1","unstructured":"Ferric citrate tablets new drug application [Internet]. [cited 2015 Jan 8]. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/205874Orig1s000TOC.cfm"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.5414\/CNP74004"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.08230811"},{"key":"e_1_3_5_19_1","article-title":"Long-term effects of iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients","author":"Floege J","year":"2015","unstructured":"Floege J, Covic AC, Ketteler M, et al. Long-term effects of iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients. Nephrol Dial Transplant. 2015 Feb 16.","journal-title":"Nephrol Dial Transplant"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1159\/000341922"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2012.11.041"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.5414\/CN108119"},{"key":"e_1_3_6_2_1","volume-title":"Product Information: VELPHORO(R) oral chewable tablets, sucroferric oxyhydroxide oral chewable tablets","year":"2013","unstructured":"Product Information: VELPHORO(R) oral chewable tablets, sucroferric oxyhydroxide oral chewable tablets. Waltham, MA: Fresenius Medical Care North America (per manufactuer); 2013."},{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-194305000-00002"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI101219"},{"key":"e_1_3_6_5_1","first-page":"11","article-title":"The effects of high doses of aluminum and iron on phosphorus metabolism","volume":"92","author":"Cox G","year":"1931","unstructured":"Cox G, Dodds M, Wigman H, et al. The effects of high doses of aluminum and iron on phosphorus metabolism. J Biol Chem. 1931;92:11\u201312.","journal-title":"J Biol Chem"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/jn\/19.3.213"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V1061274"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/12.5.961"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1159\/000348805"},{"key":"e_1_3_7_2_1","unstructured":"IUPAC. Compendium of chemical terminology [Internet]. 2nd ed. [cited 2015 Jan 8]. Available from: http:\/\/goldbook.iupac.org\/C01329.html"},{"issue":"1","key":"e_1_3_7_3_1","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1128\/aem.59.1.109-113.1993","article-title":"Influence of complex structure on the biodegradation of iron-citrate complexes","volume":"59","author":"Francis AJ","year":"1993","unstructured":"Francis AJ, Dodge CJ. Influence of complex structure on the biodegradation of iron-citrate complexes. Appl Environ Microbiol. 1993;59(1):109\u2013113.","journal-title":"Appl Environ Microbiol"},{"key":"e_1_3_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinorgbio.2005.08.004"},{"key":"e_1_3_7_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-014-0080-1"},{"key":"e_1_3_7_6_1","volume-title":"Post-hoc analysis of pharmacodynamic interaction of PA21 with statins in a phase 3 study of PA21 in dialysis patients with hyperphosphatemia [abstract]","author":"Levesque V","year":"2013","unstructured":"Levesque V, Chong EMF, Moneuse P. Post-hoc analysis of pharmacodynamic interaction of PA21 with statins in a phase 3 study of PA21 in dialysis patients with hyperphosphatemia [abstract]. Atlanta, GA: American Society of Nephrology Renal Week; 2013."},{"key":"e_1_3_7_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/1753944713513061"},{"key":"e_1_3_7_8_1","volume-title":"No clinically relevant changes in vitamin D concentrations with PA21 (sucroferric oxyhydroxide; Velphoro\u00ae), a novel iron-based phosphate binder, over 52 weeks [abstract]","author":"Rastogi A","year":"2014","unstructured":"Rastogi A, Covic A, Floege J, et al. No clinically relevant changes in vitamin D concentrations with PA21 (sucroferric oxyhydroxide; Velphoro\u00ae), a novel iron-based phosphate binder, over 52 weeks [abstract]. National Kidney Foundation 2014 Clinical Meeting, Las Vegas, NV."},{"key":"e_1_3_7_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-012-9693-3"},{"key":"e_1_3_7_10_1","unstructured":"Auryxia prescribing information [Internet]. [cited 2015 Jan 8]. Available from: http:\/\/auryxia.com\/wp-content\/uploads\/Auryxia_PI_Keryx_112014.pdf"},{"key":"e_1_3_7_11_1","unstructured":"Cullen E Dange M Jabs K et al. In vitro drug-drug interaction study with KRX-0502 (ferric citrate) and four test drugs [Poster T2287]. Presented at the American Association of Pharmaceutical Scientists Annual Meeting and Exposition; 2014 Nov 2\u20136; San Diego CA."},{"key":"e_1_3_7_12_1","doi-asserted-by":"publisher","DOI":"10.1331\/JAPhA.2012.10161"},{"key":"e_1_3_7_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.1800820229"},{"key":"e_1_3_7_14_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJNRD.S40729"},{"key":"e_1_3_7_15_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737167.2015.995169"},{"key":"e_1_3_7_16_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014080842"},{"key":"e_1_3_7_17_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014090922"},{"key":"e_1_3_8_2_1","doi-asserted-by":"publisher","DOI":"10.3109\/10408444.2014.934439"},{"key":"e_1_3_8_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/17.suppl_2.13"},{"key":"e_1_3_8_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph7100990"},{"key":"e_1_3_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(12)80356-8"},{"key":"e_1_3_8_6_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2015.03.013"},{"key":"e_1_3_9_2_1","doi-asserted-by":"publisher","DOI":"10.1159\/000365787"},{"issue":"3","key":"e_1_3_9_3_1","first-page":"391","article-title":"Fibroblast growth factor 23\u2013structure, function and role in kidney diseases","volume":"21","author":"Koce\u0142ak P","year":"2012","unstructured":"Koce\u0142ak P, Olszanecka-Glinianowicz M, Chudek J. Fibroblast growth factor 23\u2013structure, function and role in kidney diseases. Adv Clin Exp Med. 2012 May\u2013Jun;21(3):391\u2013401.","journal-title":"Adv Clin Exp Med"},{"key":"e_1_3_9_4_1","first-page":"755A","article-title":"Analysis of CKD-MBD markers in a phase 3 study of PA21 and sevelamer in patients with hyperphosphatemia","volume":"24","author":"Sprague S","year":"2013","unstructured":"Sprague S, Covic A, Ketteler M, et al. Analysis of CKD-MBD markers in a phase 3 study of PA21 and sevelamer in patients with hyperphosphatemia. J Am Soc Nephrol. 2013;24:755A.","journal-title":"J Am Soc Nephrol"},{"key":"e_1_3_9_5_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2014.10.014"},{"key":"e_1_3_9_6_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.113.204792"},{"key":"e_1_3_9_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-015-0157-z"},{"key":"e_1_3_9_8_1","unstructured":"Extending our view of self: the Human Gut Microbiome Initiative (HGMI). [cited 2015 Jan 4]. Available from: http:\/\/www.genome.gov\/Pages\/Research\/Sequencing\/SeqProposals\/HGMISeq.pdf"},{"key":"e_1_3_9_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/1574-6976.12086"},{"key":"e_1_3_9_10_1","doi-asserted-by":"publisher","DOI":"10.1159\/000366519"}],"updated-by":[{"DOI":"10.1517\/17425255.2016.1127670","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2015,12,11]],"date-time":"2015-12-11T00:00:00Z","timestamp":1449792000000}}],"container-title":["Expert Opinion on Drug Metabolism & Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/17425255.2016.1110573","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T13:21:28Z","timestamp":1770902488000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1517\/17425255.2016.1110573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,16]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1,2]]}},"alternative-id":["10.1517\/17425255.2016.1110573"],"URL":"https:\/\/doi.org\/10.1517\/17425255.2016.1110573","relation":{},"ISSN":["1742-5255","1744-7607"],"issn-type":[{"value":"1742-5255","type":"print"},{"value":"1744-7607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,16]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2015-11-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}